Meconium Methadone Screen with Reflex Confirmation
Use
The Meconium Methadone Screen with Reflex Confirmation test is clinically significant for detecting the presence of methadone exposure in neonates. Methadone is commonly used in treatment programs for opioid addiction, and its presence in a newborn could indicate maternal exposure during pregnancy. This test helps in assessing potential withdrawal symptoms and the need for medical intervention. It is important for guiding care and management of the infant in the neonatal period.
Special Instructions
Note: If the screening test is positive, the Meconium Methadone Confirmation (FMTHM) will be performed at no additional charge.
Limitations
This test may not detect methadone exposure if the exposure occurred late in the pregnancy or if the drug was not sufficiently present in the meconium collected. Additionally, the sensitivity and specificity of the test could be influenced by the quality and quantity of the meconium sample collected. Specimens that are pooled from different voids may also affect the accuracy of the test results.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 43595-8
- 43595-8
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
3 g
Minimum Volume
1 g
Container
Sterile collection container
Collection Instructions
Collect specimen into the same sterile collection container until 3 g of meconium have been collected or until the first milk stool appears. When at least 3 g of meconium has been collected, tightly screw on the cap of the collection vial and send specimen ambient. Note: Specimens from different voids may be pooled if necessary.
Causes for Rejection
NA
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 365 days |